In Brief: Allegiance/J&J
This article was originally published in The Gray Sheet
Executive Summary
Allegiance/J&J: Baxter health-care product and cost-management services business, set to be spun off later this year, inks three-year preferred supplier agreement with Johnson & Johnson's Ethicon and Ethicon Endo-Surgery businesses. J&J's products will be offered by Allegiance as part of its "best value" strategy which "involves consolidating [Allegiance's] business around preferred products in dozens of supply categories" to "improve service and value" while reducing costs, Allegiance explains...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.